PSC
LEGN icon

Patient Square Capital’s Legend Biotech LEGN Stock Holding History

Patient Square Capital’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-990,000
Closed -$17.9M – 30
2026
Q1 		$17.9M Buy
+990,000
New +$18.9M 3.18% 8

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Patient Square Capital's LEGN Position: Q2 2026 in Review

Patient Square Capital sold out of Legend Biotech (LEGN) in Q2 2026, closing a stake of 990,000 shares — an estimated $17.9M sold.

Patient Square Capital first reported a position in LEGN in Q1 2026 and held it in 1 quarter. The position peaked at $17.9M in Q1 2026. 219 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • Patient Square Capital reported no remaining Legend Biotech position as of Q2 2026 after selling out during the quarter.
  • Patient Square Capital sold 990,000 Legend Biotech shares in Q2 2026, an estimated $17.9M.
  • Patient Square Capital first reported a position in Legend Biotech in Q1 2026 and held it in 1 quarter.
  • Patient Square Capital's Legend Biotech position peaked at $17.9M in Q1 2026.
  • 219 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Patient Square Capital's 13F filing for Q2 2026, filed 12 Aug 2026.